What to do: Contact your pharmacy to confirm if you are taking medication from the affected lot. If you are, stop taking it and return it to your pharmacy for a replacement product and proper disposal.
Who this is for: General public
Affected products
Product
DIN
Lot
Expiry
Jamp-Atorvastatin 40 mg tablets
02391074
MHC1403A
2023-09-30
Issue
Jamp Pharma Corporation is recalling one lot (MHC1403A) of Jamp-Atorvastatin 40 mg tablets due to possible contamination with latex pieces during manufacturing. A piece of latex was found in one tablet from the affected lot.
Atorvastatin is a prescription drug used to treat high cholesterol and other fats (such as triglycerides) in the blood, and to prevent cardiovascular disease such as heart attacks.
Ingesting latex can pose serious health risks for people with latex allergies, including severe allergic reactions (anaphylaxis). Symptoms of anaphylaxis include breathing difficulties, nausea, vomiting, and low blood pressure. Anaphylaxis can be life threatening. In addition, foreign material in the tablets may change their shape, which could make them difficult to swallow and lead to choking.
The Department is monitoring the company's recall and will inform Canadians if any new health risks are identified.
What you should do
Contact your pharmacy to confirm if you are taking medication from the affected lot. If you are, stop taking it and return it to your pharmacy for a replacement product and proper disposal.
Contact Jamp Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at [email protected], if you have questions about this recall.
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...
Product: Meat and vegetable products
Issue: Food - Microbial Contamination - Listeria
Distribution:British Columbia
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...